Company Analysis
Sign in

Aurinia Pharmaceuticals Inc (AUPH)

Nasdaq: AUPH · Pharmaceutical Preparations · Edmonton, AB · filing with the SEC since 2014
Full chart Alerts Compare
Grade6.8
◀ Past 8.2● Present 6.8▶ Future 5.5
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

8 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Aurinia Pharmaceuticals Inc’s names, not what it holds today.

Patents granted
8
7 utility, 1 reissue, 1976 to Dec 31, 2025
Granted in 2025
none
Against none in 2024 and 1 in 2023
Applications published
19
2 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals2
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
AURINIA PHARMACEUTICALS INC. its own name
CA, as the owner printed on each patent
8 granted
12 published
Aurinia Pharmaceuticals Inc. its own name
named as the applicant on its applications, in CA
0 granted
7 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Apr 11, 202311,622,991Protocol for treatment of lupus nephritisPharmaceuticalsAURINIA PHARMACEUTICALS INC.
Apr 13, 202110,973,871Ophthalmic compositionsPharmaceuticalsAURINIA PHARMACEUTICALS INC.
Sep 29, 2020RE48,226Cyclosporine analogue mixtures and their use as immunomodulating agentsAURINIA PHARMACEUTICALS INC.
Nov 12, 201910,472,394Cyclosporine analogue mixtures and their use as immunomodulating agentsPharmaceuticalsAURINIA PHARMACEUTICALS INC.
May 14, 201910,286,036Protocol for treatment of lupus nephritisPharmaceuticalsAURINIA PHARMACEUTICALS INC.
Apr 23, 201910,265,375Ophthalmic compositionsPharmaceuticalsAURINIA PHARMACEUTICALS INC.
Sep 19, 20179,765,119Cyclosporine analogue mixtures and their use as immunomodulating agentsPharmaceuticalsAURINIA PHARMACEUTICALS INC.
Apr 28, 20159,017,725Topical drug delivery systems for ophthalmic usePharmaceuticalsAURINIA PHARMACEUTICALS INC.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Jun 26, 20252025/0205303PROTOCOL FOR TREATMENT OF LUPUS NEPHRITISPharmaceuticalsAurinia Pharmaceuticals Inc.
Feb 6, 20252025/0042970B CELL ACTIVATING FACTOR (BAFF)-A PROLIFERATION INDUCING LIGAND (APRIL) DUAL INHIBITORSPharmaceuticalsAURINIA PHARMACEUTICALS INC.
Mar 7, 20242024/0077469PROTOCOL TO MINIMIZE CALCINEURIN INHIBITOR NEPHROTOXICITYAnalysis of biological materialsAURINIA PHARMACEUTICALS INC.
Nov 30, 20232023/0381271PROTOCOL TO MINIMIZE CALCINEURIN INHIBITOR NEPHROTOXICITYAnalysis of biological materialsAURINIA PHARMACEUTICALS INC.
Jun 15, 20232023/0183293METHODS OF TREATING OR PREVENTING CORONAVIRUS INFECTIONPharmaceuticalsAURINIA PHARMACEUTICALS INC.
Jul 21, 20222022/0226428PROTOCOL FOR TREATMENT OF LUPUS NEPHRITISPharmaceuticalsAURINIA PHARMACEUTICALS INC. · patent 11,622,991 granted from it
Nov 4, 20212021/0338769OPHTHALMIC COMPOSITIONSPharmaceuticalsAURINIA PHARMACEUTICALS INC.
Jan 9, 20202020/0009217Ophthalmic CompositionsPharmaceuticalsAurinia Pharmaceuticals Inc. · patent 10,973,871 granted from it
Jul 25, 20192019/0224275PROTOCOL FOR TREATMENT OF LUPUS NEPHRITISPharmaceuticalsAURINIA PHARMACEUTICALS INC.
Nov 15, 20182018/0325995PROTOCOL FOR TREATMENT OF LUPUS NEPHRITISPharmaceuticalsAURINIA PHARMACEUTICALS INC. · patent 10,286,036 granted from it
What it applied for, 2024 to 2025: Pharmaceuticals 2 · Analysis of biological materials 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton AUPH · research, not advice